Annexon
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1400 Sierra Point Pkwy Bldg C Ste 200, B...Phone Number
(650) 822-5500Website
www.annexonbio.comRevenue
$21.8 MillionStock Symbol
ANNXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Annexon
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company's pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company's first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company's second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Based on learnings from its initial trials, Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disRead more
Annexon Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Annexon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Annexon has new funding data
Product Launch: Get notified when Annexon launches new products
Annexon, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Annexon is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Annexon
Click to see if Annexon had a recent Job posting/layoffs
Check if Annexon has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Annexon recently announced quarterly report
Recommended Actions
Find VP level buyers at Annexon
Find 2 more new buyers
Compare Similar Companies to Annexon
Compare insights from companies similar to Annexon, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Annexon is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Annexon is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Annexon.
Annexon financials insights
Gather financial insights about Annexon, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$34M
2016
Series B
$44M
2018
Series C
$75M
2020
Unspecified
$100M
Stock Offering
$250.8M
2022
Share Placement
$130M
Annexon Tech Stack
A closer look at the technologies used by Annexon
Most Recent Scoops
Open Position
Person-Based
Earnings, Research & Development, Finance
Open Position
Project
anticipates submitting a Biologics License Application (BLA) in the US for its Guillain-Barré syndrome therapy in 2026, following the release of FORT study data.
Medical Research, Pharmaceuticals
Project
Pharmaceuticals, Regulations
Annexon News & Media
Annexon Q2 Earnings Call Highlights
Annexon (NASDAQ:ANNX) said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study’s existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of theAnnexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of an open-label extension (OLE) study of vonaprument for the treatment ofAnnexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
Over Four Decades of Clinical, Scientific and Corporate Leadership Advancing Innovation in Retinal Disease Over Four Decades of Clinical, Scientific and Corporate Leadership Advancing Innovation in Retinal Disease
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Annexon
Sign Up For FreeTo access detailed company insights
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company's pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, b... Read More
